| Document |
Document Title |
|
WO/1995/029167A1 |
The invention relates to novel substituted cyclopropylcarbonyl-phenylaminosulphonyl ureas of formula (I) in which the constituents R1, R2, R3 and R4 have the meanings given in the description and R5 is optionally halogen or C1-C4 alkyl-s...
|
|
WO/1995/026327A1 |
The use of a compound of formula (I), wherein X represents O, S, C=O or a bond; p and q independently represent 0-4; R1 and R2 each independently represent hydrogen, C1-6alkyl, C3-6cycloalkyl or C3-6cycloalkylC1-4alkyl; n is 1, 2, 3 or 4...
|
|
WO/1995/022546A1 |
Therapeutic compounds with at least one carboxylic, acid, ester or amide-substituted moiety have the formula: TERMINAL MOIETY-(R)j. In the formula, j is an integer from one to three, the terminal moiety is an aliphatic chemical moiety or...
|
|
WO/1995/022520A1 |
A compound of structure (I), wherein, when R8 = H: R1 = alkyl, cycloalkyl, arylalkyl, aryl; R2 = cycloalkyl, aryl, C3-C10 alkyl; X, Y = O, S(O)n, NH; Z = CH2OH, NHSO2R3, CHO, CO2R3, CONHR4R5, CN, COR6, H, halo, NHCN, NHCONR4R5, CONR4OR5,...
|
|
WO/1995/021813A1 |
This invention concerns compounds of generic formula (I) or a pharmaceutically acceptable salt thereof, where the dotted line represents an optional bond, one of R1 and R5 represents hydrogen, C1-C6 alkyl, C7-C16 aralkyl, -(CHR6)nCHR7CN,...
|
|
WO/1995/018092A1 |
An amino ketone derivative represented by general formula (I), a physiologically acceptable salt thereof, a process for producing the same, and a central muscle relaxant and a remedy for frequent urination each containing the derivative ...
|
|
WO/1995/011224A1 |
Intermediates and processes are disclosed which are useful for the preparation of a substantially pure compound of formula (3), wherein R6 and R7 are each hydrogen or R6 and R7 are independently selected from (i), wherein Ra and Rb are i...
|
|
WO/1995/011221A1 |
The present invention features molecules with general structure (I) or (II) which can modulate on or activities of an inorganic ion receptor. Preferably, the molecule can mimic or block the effect of extracellular Ca2+ on a calcium recep...
|
|
WO/1995/010545A1 |
The present invention relates to a novel process for the production of fuel and lubricant additives useful as dispersants and multifunctional viscosity modifiers wherein a dihydroxyaromatic compound is alkylated with an olefinic polymer ...
|
|
WO/1995/009149A1 |
A compound having structural formula (I), where R1 and R2 are independently hydrogen or hydroxyl, R2 and R3 are independently oxo or hydrogen, one of R5 and R6 is A-B and the other is hydrogen, hydroxyl, or a group A, wherein the or each...
|
|
WO/1995/009379A1 |
The invention is in the field of retardation layers comprising high-molecular weight liquid-crystalline material for liquid-crystalline displays. The invention is directed to a retardation layer for a liquid-crystalline display comprisin...
|
|
WO/1995/007885A1 |
Compounds of formula (I), wherein R is a hydrogen atom or an OY group; R1 is a hydrogen atom or an OY' group; R2 is a hydrogen atom or an OY'' group; provided that at least one among R, R1 and R2 is hydrogen but R, R1 and R2 are not cont...
|
|
WO/1995/005805A1 |
The present invention relates to a process for providing a stable crystallinic form to a fine-grained substance or a substance mixture, which can be produced, stored and used while maintaining the aerodynamic properties required for inha...
|
|
WO/1995/004713A1 |
Compounds and their pharmaceutically acceptable salts suitable for treating central nervous system disorders associated with the dopamine D3 receptor activity of formula (I), wherein R1 and R2 are independently chosen from hydrogen, C1-C...
|
|
WO/1995/003791A1 |
This application discloses a method of inhibiting degradation of the antidepressant bupropion hydrochloride in a solid pharmaceutical formulation, so that the pharmaceutical formulation will maintain at least 80 % of its initial bupropio...
|
|
WO/1995/003267A1 |
The present invention relates to 1,2-benzoquinones; methods of preparation of 1,2-benzoquinones that include preparation of 4,5-substituted- 1,2-benzoquinones in a one-pot reaction; and methods of treatment and pharmaceutical composition...
|
|
WO/1995/003270A1 |
The invention relates to new N,N,N',N'-tetra-substituted-1,2-ethanediamine compounds of general formula (I), wherein X is a carbonyl (CO), hydroxymethylen (CHOH) or p-fluorophenyl-methylen (p-F-C6H4-CH) group and R is a benzyl group opti...
|
|
WO/1995/000476A1 |
Novel beta-aminovinyl ketones of general formula (VI), wherein R1 is, in particular, an alkenyl, alkynyl, cycloalkyl or cycloalkenyl group; R2 is, in particular, an electron attracting substituent such as nitro, acyl, ester, alkylthio, c...
|
|
WO/1995/000468A1 |
The present invention provides novel fluorenone derivatives represented by formula (A) (wherein Ra-Rg are defined in the specification), and a method for repairing and protecting central or peripheral nerve degeneration comprising use of...
|
|
WO/1995/000131A1 |
The invention relates to methods for the treatment of central nervous system disorders, neurological disorders, gastrointestinal disorders, drug abuse, angina, migraine, hypertension and depression by administering a pharmaceutical compo...
|
|
WO/1994/029255A1 |
Compounds of general formula (I), stereoisomers and pharmaceutically acceptable salts thereof, wherein each of Z and Z' are independently H or F; Q is (a), CH(OH), (b); X is H, Br, Cl, F or CF3; Y is H, Br, Cl, F, OH, OR5, OC(O)R4, N3, C...
|
|
WO/1994/029277A1 |
A compound of formula (1) or a pharmaceutically acceptable salt thereof, wherein Ar is an optionally substituted aryl or heteroaryl ring selected from phenyl, naphthyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, imidazolyl, thienyl, oxa...
|
|
WO/1994/027965A1 |
The present invention relates to novel 5-HT4 receptor ligands which are 1-(5-halo-4-aminophenyl) (C2-6)alkan-1-one derivatives in which the 5-halo-4-aminophenyl group is substituted at its 2-position with (C1-4)alkyloxy or phenyl(C1-4)al...
|
|
WO/1994/027947A1 |
This invention relates to substituted phenylcyclopropane derivatives, which carry various substituents on the cyclopropane ring, to processes for their preparation, to pharmaceutical compositions containing them, and to methods for their...
|
|
WO/1994/017018A1 |
A fullerene derivate has formula (I), in which the symbols and indexes have the following meaning: F is a fullerene residue having the formula (C20+2m), in which m equals 1 to 50; R1 to R8 are the same or different and represent H, CO2R9...
|
|
WO/1994/015258A1 |
A polymer has at least one photoactive site and more than one perfluorocyclobutane group. New monomers containing photoactive sites or photoactive precursors and at least one perfluorovinyl group are useful for making such polymers. Proc...
|
|
WO/1994/014754A1 |
An anilinium salt compound represented by general formula (I) and a cationic polymerization initiator containing at least one said compound, wherein R1 represents hydrogen, alkyl, etc.; R2 represents alkyl, etc.; R3 represents alkyl subs...
|
|
WO/1994/008943A1 |
A 2-amino-1,3-propanediol compound represented by general formula (I) or a pharmaceutically acceptable salt thereof, and an immunosuppressant containing the same as the active ingredient. In said formula R represents optionally substitut...
|
|
WO/1994/005619A1 |
An optically active compound represented by general formula (I), a mixture thereof, and a carcinostatic and osteogenesis promoter each containing the same as the active ingredient, wherein Y represents hydrogen or halogen; A represents h...
|
|
WO/1994/004485A1 |
Ligands and compositions for gallium-68 PET heart imaging are disclosed. The ligands form stable complexes with Ga-68. Variation of pendant substituents permits organ targeting with perfusion characteristics akin to a potassium mimic. Ma...
|
|
WO/1994/002442A1 |
Novel compounds of general formula (I), wherein R1 is selected from alkyl, alkoxy, alkenyloxy, arylalkoxy, alkylthio and alkenylthio; R2 is selected from halogen, hydroxy, alkyl, alkoxy, alkenyloxy, alkylthio, alkenylthio, alkylamino, tr...
|
|
WO/1994/001474A1 |
A polymerizable monomer represented by general formula (1), a polymer thereof, a process for producing the same, and the use of the polymer, wherein R1 represents hydrogen, methyl, chloro or cyano; R2 represents C1-C4 alkylene; R3 repres...
|
|
WO/1994/000420A1 |
Inhibitors of leukotriene A4 hydrolase are disclosed, as are processes for making and using the same. A contemplated inhibitor has a structure corresponding to formula (I), wherein the depicted -NH2 group is in the (S) configuration; -W ...
|
|
WO/1993/024446A1 |
A compound having anthelmintic and/or nematocidal activity, having general formula (I) or (II); wherein X and Y which may be the same or different, each represents a heteroatom; R¿1?, R¿3? and R¿4?, which may be the same or different,...
|
|
WO/1993/023364A1 |
Novel 2,5 dihydroxybenzylamine derivatives of general formula (I), their preparation and pharmaceutical compositions containing same. In general formula (I), one of the symbols R1 or R2 denots a hydrogen or halo atom or a hydroxy, alkoxy...
|
|
WO/1993/022279A1 |
Diamine derivatives of formula (I), wherein n = 0-8; R1 is hydrogen or a C1-3 alkyl residue; each of R2, R3, R4, R5 and R6 is hydrogen, a C1-6 alkyl residue, branched C4-12 alkyl or alkenyl; R2 and R3 together may form a C3-8 ring option...
|
|
WO/1993/022259A1 |
The invention relates to a process for producing 1,4-bisaryl-butane-1,4-diones having general formula (I) where R and R' independently denote substituted or unsubstituted aromatic or heteroaromatic groups and polymers thereof from 1,4-bi...
|
|
WO/1993/017671A1 |
Aromatic compounds, or prodrugs thereof, which contain an alkylating site and which are capable of alkylating the thiol group in N-acetyl-L-cysteine, in particular bis-aromatic $g(a),$g(b)-unsaturated ketones, are used for the preparatio...
|
|
WO/1993/017678A1 |
Enaminones which display anticonvulsant activity having formula (I) wherein R is from the group consisting of COOCH3 and COOC2H5; R1 is from the group consisting of H and CH3; R2 is from the group consisting of H and CH3; and R3 is from ...
|
|
WO/1993/016969A1 |
A process is provided for the catalytic perfluoroalkylation of aromatic compounds, wherein a perfluoroalkyl iodide or mixture of iodides is reacted with an aromatic compound in the presence of an aqueous base, such as an alkali metal hyd...
|
|
WO/1993/015607A1 |
Ion pairs of hypericin and its analogues and derivatives are prepared by acidifying hypericin to its free acid form and reacting with a predetermined quantity of an organic or inorganic base at a pH below about 11.5. The compounds are us...
|
|
WO/1993/013052A1 |
The present invention is concerned with antiretroviral (e.g. anti HIV-1) compounds having formula (I-a) or (I-b). Pharmaceutical compositions containing said compounds of formula (I-a) or (I-b), and processes of preparing said compounds ...
|
|
WO/1993/013099A1 |
Heterocyclic compound of the formula: R1-A-CO-X-Y-R2, in which R1 is carboxy(lower)alkyl or protected carboxy(lower)alkyl, R2 is optionally substituted aralkyl, X is optionally substituted arylene, Y is -O- or (a), wherein R6 is hydrogen...
|
|
WO/1993/004099A1 |
Rigid-rod macromonomers, and methods for preparing such macromonomers, having a polyaromatic backbone, solubilizing side groups, and reactive end groups are provided. The macromonomers are chemically incorporated into polymer systems to ...
|
|
WO/1993/004098A1 |
Rigid-rod macromonomers, and methods for preparing such macromonomers, having a polyaromatic backbone, solubilizing side groups, and reactive side groups are provided. The macromonomers are chemically incorporated into polymer systems to...
|
|
WO/1993/004373A1 |
Method and composition useful for treating a patient having a disease characterized by an abnormal level of one or more components, the activity of which is regulated or affected by activity of one or more Ca?2+¿ receptors. Novel compou...
|
|
WO/1993/000313A2 |
The invention relates to methods for the treatment of central nervous system disorders, gastrointestinal disorders, drug abuse, angina, migraine, hypertension and depression by administering a pharmaceutical composition comprising an eff...
|
|
WO/1992/019586A1 |
Disclosed is a process for the preparation of 1-amino-4-bromoanthraquinones by the bromination of the corresponding 1-aminoanthraquinone wherein a 1-amino-anthraquinone is contacted with elemental bromine in the presence of a carboxylic ...
|
|
WO/1992/018564A2 |
A method of manufacturing 3-amino-2-cyclohexene-1-one by hydrogenating m-phenylenediamene to produce a novel intermediate salt of 3-amino-2-cyclohexene-1-imine followed by hydrolysis to produce 3-amino-2-cyclohexene-1-one. The novel inte...
|
|
WO/1992/015319A1 |
The invention relates to HIV protease inhibitors wherein the compounds have a 2,4-dihydroxy isostere wherein the hydroxyl group in the 2-position is further substituted to create a tertiary alcohol. Also disclosed are pharmaceutically ac...
|
